A
Andreas Reichel
Researcher at Bayer HealthCare Pharmaceuticals
Publications - 64
Citations - 2111
Andreas Reichel is an academic researcher from Bayer HealthCare Pharmaceuticals. The author has contributed to research in topics: Blood–brain barrier & P-glycoprotein. The author has an hindex of 23, co-authored 60 publications receiving 1915 citations. Previous affiliations of Andreas Reichel include King's College London & Schering AG.
Papers
More filters
Journal ArticleDOI
Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
TL;DR: Despite enormous efforts, achieving a safe and efficacious concentration profile in the brain remains one of the big challenges in central nervous system (CNS) drug discovery and development.
Journal ArticleDOI
Interaction of Poly(butylcyanoacrylate) Nanoparticles with the Blood-Brain Barrier in vivo and in vitro
Renad N. Alyaudtin,Andreas Reichel,Raimar Löbenberg,Peter Ramge,Jörg Kreuter,David J. Begley +5 more
TL;DR: The hypothesis that the mechanism of blood-brain barrier transport of drugs by polysorbate 80-coated nanoparticles is one of endocytosis followed by possible transcytosis is supported.
Journal ArticleDOI
Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats.
TL;DR: All transporters showed considerable intra- and interindividual variability, especially at the protein level, making it problematic to take transporter expressions of small sections exemplary for general assumptions on intestinal abundances.
Journal ArticleDOI
The role of blood-brain barrier studies in the pharmaceutical industry.
TL;DR: This review will elaborate on the specific needs in terms of BBB-related issues across the different drug discovery and development phases, i.e. target identification and validation, lead generation and optimization, candidate selection and profiling, preclinical development and clinical studies.
Journal ArticleDOI
The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer
Ulrich Lücking,Rolf Jautelat,Martin Krüger,Thomas Brumby,Philip Lienau,Martina Schäfer,Hans Briem,Julia Schulze,Alexander Hillisch,Andreas Reichel,Antje Margret Wengner,Gerhard Siemeister +11 more
TL;DR: Lead optimization of a high‐throughput screening hit led to the rapid identification of aminopyrimidine ZK 304709, a multitargeted CDK and VEGF‐R inhibitor that displayed a promising preclinical profile, but failed in phase I studies due to dose‐limited absorption and high inter‐patient variability.